Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?

Author(s):  Shakshuki Ayah, Agu Remigius U

Issue:  Nov/Dec 2019 - Volume 23, Number 6
View All Articles in Issue

Abstract:  The objective of this study was to investigate the effect of Lipoderm Cream, VersaBase Gel, and Emollient Cream on the release and permeation of gabapentin formulated for neuropathic pain. Gabapentin of different strengths (1%, 5%, and 10%) was compounded with the bases, diffusion of the drug from thebases, and permeation through artificial skin model studied with Franz diffusionsystem. Steady-state flux, cumulative permeation, and lag times were calculated,and release mechanisms modelled with first order, second-order, Higuchi, Korsmeyer-Peppas, and Hixon-Crowell kinetic models. Gabapentin recovery from VersaBase Gel, Lipoderm Cream, and Emollient Cream was 100.8 ± 2.7%, 101.3 ± 1.2%, and 104.9 ± 3.3%, respectively. Gabapentin completely diffused out of the three bases within 6 hours of application according to the Higuchi model. Flux of the drug appeared to be concentration-dependent with no permeation occurring at 1% strength. Whereas, 5% and 10% strengths in Lipoderm Cream permeated the skin rapidly, the same concentrations in Emollient Cream and VersaBase Gel required 60-minutes and 120-minutes lag times, respectively. For the three bases, a strong correlation was observed between lag times and flux. The overall permeation in VersaBase Gel and Lipoderm Base was not significantly different (P>0.05). However, Emollient Cream resulted in a significantly lower total permeation compared to other bases (P<0.05). As the formulations are for pain management, products with no lag times and higher flux are preferable. Although VersaBase Gel and Emollient Cream displayed some gabapentin permeability, it is important to consider gabapentin stability in these bases prior to use.

Related Keywords: Ayah Shakshuki, BSc (Pharmacy), MSc, Remigius U. Agu, MPharm (Pharmacology), MPharm (Pharmaceutics), PhD, gabapentin, voltage-dependent calcium channel inhibitor, NMDA inhibitor, topical preparation, cream base, gel base, neuropathic pain, pain relief, postherpetic neuralgia, skin permeation, drug release modeling, simulated human skin


Printer-Friendly Version

Download in electronic PDF format for $55

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy? Shakshuki Ayah, Agu Remigius U Nov/Dec 2019 496-503 Buy
Stability Assessment of Topical Amitriptyline Extemporaneously Compounded with Lipoderm Base, PLO Gel Mediflo 30, and Emollient Cream Shakshuki Ayah, Agu Remigius U Jan/Feb 2019 82-87 Buy
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases Teimouri Arezou, Yeung Pollen, Agu Remigius U Jul/Aug 2021 344-351 Buy
Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing Teimouri Arezou, Yeung Pollen, Agu Remigius U Nov/Dec 2020 501-508 Buy
Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use Teimouri Arezou, Yeung Pollen, Agu Remigius U Nov/Dec 2020 482-490 Buy
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott Mar/Apr 2015 167-173 Buy
Compounded Pain Formulations: What is the Evidence? Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso Jul/Aug 2014 278-286 Buy
Compounding Pearls -- Wound Care: Base Selection Riepl Mike Mar/Apr 2020 98-102 Buy
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III May/Jun 2010 182-192 Buy
Topical Medications for Orofacial Neuropathic Pain Bramwell Bethany L May/Jun 2010 200-203 Buy